Traumatic Brain Injury May Up Risk for Developing Comorbidities
FRIDAY, April 29, 2022 (HealthDay News) — Traumatic brain injury (TBI) of any severity is associated with increased risk of chronic cardiovascular, endocrine, and neurologic comorbidities, according to a study published online April 28 in JAMA Networ…
Learn MoreSexual Minority Students Perceive Medical School Less Favorably
FRIDAY, April 29, 2022 (HealthDay News) — Compared with heterosexual students, sexual minority (SM) students have less favorable perceptions of the medical school learning environment, according to a study published online April 29 in JAMA Network Op…
Learn MoreReview: Transcranial Direct Current Stimulation Eases Migraine
FRIDAY, April 29, 2022 (HealthDay News) — Transcranial direct current stimulation (tDCS) is effective and safe for migraine, according to a review published online April 19 in CNS Neuroscience and Therapeutics.Peiwei Hong, from Sichuan University in …
Learn MoreMigraine May Raise Risk for Burning Mouth Syndrome
FRIDAY, April 29, 2022 (HealthDay News) — Migraine is associated with an increased risk for burning mouth syndrome (BMS), according to a study published online April 11 in the Journal of Personalized Medicine.Dong-Kyu Kim, M.D., Ph.D., from the Hally…
Learn MoreLink Between GI Issues, Internalizing Symptoms Studied in Autism
FRIDAY, April 29, 2022 (HealthDay News) — For children with autism spectrum disorder (ASD), a bidirectional relationship may exist between gastrointestinal (GI) issues and internalizing symptoms, according to a study published online April 20 in the …
Learn MoreCigarette Smoking Down for Adults With Behavioral Health Conditions
FRIDAY, April 29, 2022 (HealthDay News) — There were significant reductions in the prevalence of self-reported cigarette smoking among U.S. adults with major depressive episode (MDE), substance use disorder (SUD), or both between 2006 and 2019, accor…
Learn MoreMany Infants in WIC Program Not Getting Enough Vitamin D
FRIDAY, April 29, 2022 (HealthDay News) — A high proportion of infants in the Supplemental Nutrition Program for Women, Infants, and Children (WIC) are not meeting current vitamin D recommendations, according to a study published online March 11 in t…
Learn MoreDapagliflozin Well Tolerated in COVID-19 Patients, Regardless of eGFR
FRIDAY, April 29, 2022 (HealthDay News) — The effects of dapagliflozin are similar for hospitalized patients with COVID-19 with estimated glomerular filtration rate (eGFR) 2, according to a study published online April 28 in the Clinical Journal of the American Society of Nephrology.
Hiddo J. L. Heerspink, Ph.D., Pharm.D., from the University Medical Center Groningen in the Netherlands, and colleagues conducted a secondary analysis of the Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial, which randomly assigned 1,250 hospitalized patients with COVID-19 and cardiometabolic risk factors to dapagliflozin or placebo. Dual primary outcomes (time to new or worsened organ dysfunction or death, and a hierarchical composite end point of recovery) and key secondary kidney outcomes were assessed among those with baseline eGFR 2.
The researchers found that across eGFR subgroups, the effect of dapagliflozin versus placebo was consistent on the primary prevention outcome (hazard ratio, 0.80; 95 percent confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95 percent confidence interval, 0.97 to 1.22), and the composite kidney outcome (hazard ratio, 0.74; 95 percent confidence interval, 0.50 to 1.07; P for interaction, 0.98, 0.67, and 0.44, respectively). The effects of dapagliflozin on acute kidney injury were also similar for those with eGFR 2 (hazard ratio, 0.71; 95 percent confidence interval, 0.29 to 1.77) and ≥60 mL/min per 1.73 m2 (hazard ratio, 0.69; 95 percent confidence interval, 0.37 to 1.29). In patients with eGFR 2, dapagliflozin was well tolerated.
“These new data from DARE-19 reinforce the safety of dapagliflozin in acutely ill patients hospitalized with COVID-19 even in those with reduced kidney function who are at particularly high risk of acute kidney injury,” Heerspink said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which manufactures dapagliflozin and funded the study.
Learn MoreRacial Differences Seen for Joint Replacement Care and Outcomes
FRIDAY, April 29, 2022 (HealthDay News) — Racial differences persist across the continuum of care among patients undergoing total joint arthroplasty (TJA), according to a study published in the April 15 issue of the Journal of Bone and Joint Surgery….
Learn MoreFDA Proposes Ban on Menthol Cigarettes, Flavored Cigars
THURSDAY, April 28, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday released proposed rules — first announced a year ago — to ban menthol cigarettes and flavored cigars.”The proposed rules would help prevent children from …
Learn More